[Prognostic Value of Donor Chimerism at +90 Days After Allogeneic Hematopoietic Stem Cell Transplantation in Young Patients with Intermediate-risk Acute Myeloid Leukemia]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2020 Feb 7

PMID 32023728

Authors

Y Fei

X X Hu

Q Chen

A J Huang

H Cheng

X Ni

H Y Qiu

L Gao

G S Tang

J Chen

W P Zhang

J M Yang

J M Wang

Affiliations

Soon will be listed here.

Abstract

To investigate the relationship between donor chimerism and relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . The clinical data of 105 patients with acute myeloid leukemia (AML) who underwent allo-HSCT and recurrence-free survival>90 days from January 2010 to January 2019 were retrospectively analyzed. The bone marrow samples were collected at 15, 30, 60, 90, 180, 270, 360 days after transplantation. Donor chimerism was detected by single nucleotide polymorphism (SNP) -PCR. Of the 105 patients, 43 cases were male and 62 cases were female, with a median age of 38 (16-60) years. Till April 2019, the median follow-up was 843 (94-3 261) days. Ninety days after transplantation, 18 cases relapsed, 33 cases died, and 72 cases survived. The 3-year overall survival (OS) rate was (66.8±5.1) %, and the recurrence-free survival (RFS) rate was (65.1±5.0) %. Pre-transplant disease status, pre-transplant minimal residual disease (MRD) , and 90 day post-transplantation chimerism were independent risk factors related to RFS. The risk of recurrence was significantly increased in patients with a donor chimerism rate ≤97.24% at 90 days after transplantation[=6.921 (95% 2.669-17.950) , <0.001], which was considered as a sign of early relapse. SNP-PCR is an applicable method for detecting donor chimerism in patients after allo-HSCT. Chimerism rate equal or less than 97.24% at 90 days after transplantation predicts a higher risk of relapse.

References

Rashidi A, Linden M, Percival M, Sandmaier B, Devine S, Weisdorf D . Recommendations for reporting post-transplant relapse in AML. Bone Marrow Transplant. 2017; 53(2):111-113. DOI: 10.1038/bmt.2017.227. View

Rautenberg C, Germing U, Haas R, Kobbe G, Schroeder T . Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment. Int J Mol Sci. 2019; 20(1). PMC: 6337734. DOI: 10.3390/ijms20010228. View

Zhang W, Wang Z, Hu X, Chen J, Yang D, Song X . Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study. Bone Marrow Transplant. 2018; 54(6):894-902. DOI: 10.1038/s41409-018-0356-5. View

Cheson B, Bennett J, Kopecky K, Buchner T, Willman C, Estey E . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-9. DOI: 10.1200/JCO.2003.04.036. View

Gabr H, Youssry I, El-Ansary Y, Mosallam G, Riad N, Hanna M . Chimerism in pediatric hematopoietic stem cell transplantation and its correlation with the clinical outcome. Transpl Immunol. 2017; 45:53-58. DOI: 10.1016/j.trim.2017.09.004. View

Yafour N, Beckerich F, Bulabois C, Chevallier P, Daguindau E, Dumesnil C . How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome. Curr Res Transl Med. 2017; 65(2):65-69. DOI: 10.1016/j.retram.2017.06.001. View

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum F, Buchner T . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016; 129(4):424-447. PMC: 5291965. DOI: 10.1182/blood-2016-08-733196. View

Jiang Y, Wan L, Wang C, Yan S, Gao Y, Jiang J . [Clinical significance of dynamic monitoring of cell chimerism following allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2009; 29(10):667-71. View

Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M . Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time. Biol Blood Marrow Transplant. 2014; 20(8):1139-44. PMC: 4099297. DOI: 10.1016/j.bbmt.2014.04.003. View

10.

Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C . Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood. 2002; 99(12):4618-25. DOI: 10.1182/blood.v99.12.4618. View

11.

Baron F, Sandmaier B . Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia. 2006; 20(10):1690-700. DOI: 10.1038/sj.leu.2404335. View

12.

Huisman C, de Weger R, de Vries L, Tilanus M, Verdonck L . Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant. 2007; 39(5):285-91. DOI: 10.1038/sj.bmt.1705582. View

13.

Schuurhuis G, Heuser M, Freeman S, Bene M, Buccisano F, Cloos J . Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018; 131(12):1275-1291. PMC: 5865231. DOI: 10.1182/blood-2017-09-801498. View

14.

Tsirigotis P, Byrne M, Schmid C, Baron F, Ciceri F, Esteve J . Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant. 2016; 51(11):1431-1438. DOI: 10.1038/bmt.2016.167. View

15.

Lamba R, Abella E, Kukuruga D, Klein J, Savasan S, Abidi M . Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival. Leukemia. 2004; 18(10):1681-6. DOI: 10.1038/sj.leu.2403468. View

16.

Khan F, Agarwal A, Agrawal S . Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme. Bone Marrow Transplant. 2004; 34(1):1-12. DOI: 10.1038/sj.bmt.1704525. View

17.

de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I . Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017; 129(13):1753-1762. PMC: 5524528. DOI: 10.1182/blood-2016-06-724500. View

18.

Yang X, Wang J . Precision therapy for acute myeloid leukemia. J Hematol Oncol. 2018; 11(1):3. PMC: 5755341. DOI: 10.1186/s13045-017-0543-7. View

19.

Lee H, Saliba R, Rondon G, Chen J, Charafeddine Y, Medeiros L . Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2015; 21(11):1948-54. PMC: 4604040. DOI: 10.1016/j.bbmt.2015.07.005. View

20.

Tang X, Wu D, Xia X, Sun A, Zhu Z, Ruan C . [Sequential and quantitative analysis of chimerism after non-myeloablative stem cell transplantation]. Zhonghua Nei Ke Za Zhi. 2004; 43(2):98-101. View